Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study
Clinical Lung Cancer · 2026
DOI: 10.1016/j.cllc.2026.08.005 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Ludovica Mollica und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 38 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥ 50%; however, up to 30% of patients experience early progression or death, including cases of hyperprogressive disease (HPD). High baseline levels (≥ 30.5%) of circulating CD10- low-density neutrophils (LDNs) have been associated with increased HPD occurrence. Emerging evidence suggests that combining ICI with platinum-based chemotherapy (PCT) may mitigate the risk of HPD. Currently, no prospective studies have addressed HPD prevention in this context. PATIENTS AND METHODS: HYPERBOLIC (NCT07274384) is a phase 2, randomized, open-label, multicenter, international trial evaluating whether adding 3 cycles of PCT to first-line cemiplimab reduces HPD rate in stage IV NSCLC with PD-L1 ≥ 50% and CD10- LDNs (identified by flow cytometry as CD15⁺CD11b⁺ within the PBMC fraction, with immature cells defined by loss of CD10) ≥ 30.5%. Seventy-four patients will be randomized (1:1 ratio) to receive cemiplimab alone or cemiplimab plus 3 PCT cycles, followed by cemiplimab maintenance. Randomization will be stratified by Lung Immune Prognostic Index. The first computed tomography scan at week 7 after treatment start will assess HPD occurrence, defined as RECIST v 1.1. disease progression with a delta tumor growth rate (ΔTGR) ≥ 50% and/or TGR ratio ≥ 2. The primary endpoint will be the combined rate of HPD and early death (death within 12 weeks with no radiological evaluation). Secondary endpoints will be HPD rate according to alternative definitions, overall survival, progression free survival, objective response rate, and safety. An extensive translational research platform will include spatial transcriptomics of tumor tissue, single-cell RNA sequencing of PBMCs, circulating-free DNA and plasma factors profiling, and saliva/stool microbiome genomics and metabolomics, to longitudinally explore tumor-host dynamic interactions during treatment. CONCLUSION: to our knowledge, HYPERBOLIC is the first prospective, biomarker-driven trial investigating early treatment escalation based on HPD risk in PD-L1-high NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
- Cell Therapy Immunomonitoring Laboratory (MITiCi), Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.
- Methodology for Clinical Research Laboratory, IRCCS Mario Negri Institute for Pharmacological Research, Milan, Italy.
- San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy.
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy; Immuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Onc…
Zitieren
APA
Mollica, L., Tassi, E., Copaloni, A., De Simone, I., Barouni, R. M., De Giorgi, S., Pagano, A., Lampertico, G., Noviello, M., Ferrara, M., Garavaglia, B., Guarnieri, S., Bulotta, A., Viganò, M. G., Ogliari, F. R., Oresti, S., Damiano, G., Russo, V., Riva, S. T., …, & Cortinovis, D. L. (2026). Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.08.005
Vancouver
Mollica L, Tassi E, Copaloni A, De Simone I, Barouni RM, De Giorgi S, et al. Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.08.005
BibTeX
@article{Mollica2026,
author = {Mollica, Ludovica and Tassi, Elena and Copaloni, Anna and De Simone, Irene and Barouni, Roza Maria and De Giorgi, Silvia and Pagano, Antonella and Lampertico, Giacomo and Noviello, Maddalena and Ferrara, Michele and Garavaglia, Beatrice and Guarnieri, Sara and Bulotta, Alessandra and Viganò, Maria Grazia and Ogliari, Francesca Rita and Oresti, Sara and Damiano, Giuseppe and Russo, Vincenzo and Riva, Silvia Teresa and Nuccio, Antonio and Salomone, Fabio and Venanzi, Francesco Maria and Passaretti, Francesco and Papotto, Ludovica and Zotti, Denise and Di Lello, Anna and Carbone, Carmine and Bria, Emilio and Sistigu, Antonella and Musella, Martina and Verlicchi, Alberto and Ulivi, Paola and Genova, Carlo and Tagliamento, Marco and Ferlazzo, Guido and Russo, Giuseppe Lo and Brambilla, Marta and Pasello, Giulia and Mandruzzato, Susanna and Corbo, Vincenzo and Pilotto, Sara and De Sanctis, Francesco and Gelibter, Alain and Piconese, Silvia and Tiseo, Marcello and Mazzaschi, Giulia and Pluchino, Monica and Cappuzzo, Federico and Minuti, Gabriele and Landi, Lorenza and Nisticò, Paola and Arasanz, Hugo and Labiano, Ibone and Mezquita, Laura and Pascal, Mariona and Lavaud, Pernelle and Chaput, Nathalie and Grisanti, Salvatore and Bettini, Anna Cecilia and Cortinovis, Diego Luigi},
title = {Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study},
journal = {Clinical Lung Cancer},
year = {2026},
doi = {10.1016/j.cllc.2026.08.005}
}
EUVIMED